Allergan, anticipating generic competition for Restasis and loss of exclusivity of other products, is taking steps to strengthen its balance sheet.
Net revenues for the company’s third quarter were down 3%, which was “driven primarily by loss of exclusivity of some brands,” Allergan CEO Brent Saunders said in a press release.
Patents for Restasis (cyclosporine ophthalmic emulsion 0.05%), the company’s popular dry eye treatment, are due to begin expiring in 2024, and a controversial deal between the company and a Native American tribe to protect them longer was found to
Uncategorized